Journal Mobile Options
Table of Contents
Vol. 18, No. 5, 2009
Issue release date: August 2009
Section title: Original Paper
Open Access Gateway
Med Princ Pract 2009;18:360–363
(DOI:10.1159/000226288)

Does Imatinib Mesylate Therapy Cause Growth Hormone Deficiency?

Kebapcilar L.a · Bilgir O.b · Alacacioglu I.d · Payzin B.d · Bilgir F.c · Oner P.c · Sari I.c · Calan M.c · Binicier O.e
aDivision of Endocrinology and Metabolism, bDivision of Hematology and cDepartment of Internal Medicine, Bozyaka Training and Research Hospital, dDivision of Hematology, Department of Internal Medicine, Izmir Ataturk Training and Research Hospital,and eDepartment of Internal Medicine, Dokuz Eylul University, Izmir, Turkey
email Corresponding Author

Levent Kebapcilar

Division of Endocrinology and Metabolism

Department of Internal Medicine, Bozyaka Training and Research Hospital

123/4 Street No: 10 A flat: 4, TR–35340 Izmir (Turkey)

Tel. +90 50 5448 2857, Fax +90 238 4038, E-Mail leventkebapcilar@yahoo.com


References

  1. Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib mesylate. Pharmacol Rev 2003;55:401–423.
  2. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR: Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res 2000;55:266–267.
  3. Anderson LL, Jeftinija S, Scanes CG: Growth hormone secretion: molecular and cellular mechanisms and in vivo approaches. Exp Biol Med (Maywood) 2004;229:291–302.
  4. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML: Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002;87:2067–2079.
  5. Boquete HR, Sobrado PG, Fideleff HL, Sequera AM, Giaccio AV, Suárez MG, Ruibal GF, Miras M: Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J Clin Endocrinol Metab 2003;10:4702–4708.

    External Resources

  6. Corneli G, Gasco V, Prodam F, Grottoli S, Aimaretti G, Ghigo E: Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood. Pituitary 2007;10:141–149.
  7. Kwan AY, Hartman ML: IGF-I measurements in the diagnosis of adult growth hormone deficiency. Pituitary 2007;10:151–157.
  8. Pastural E, Takahashi N, Dong WF, Bainbridge M, Hull A, Pearson D, Huang S, Lowsky R, DeCoteau JF, Geyer CR. RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines. Oncogene 2007;26:1586–1594.
  9. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML, Stephens PA: Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006;91:1621–1634.
  10. Oliveira MR, Ohnuma L, Bendit I, Dorlhiac-Lacer P, Giannella-Neto D: Interferon-α therapy increases type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukemia. Leuk Res 2001;25:711–717.
  11. Celniker AC, Chen AB, Wert RM Jr, Sherman BM: Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989;68:469–476.
  12. Granada ML, Ulied A, Casanueva FF, Pico A, Lucas T, Torres E, Sanmartí A: Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population. Clin Endocrinol (Oxf) 2008;68:942–950.
  13. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908–916.